EPS for Amphastar Pharmaceuticals, Inc. (AMPH) Expected At $0.09

April 23, 2018 - By Lynda A. Deweese

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.24, from 0.91 in 2017Q3. It improved, as 5 investors sold Amphastar Pharmaceuticals, Inc. shares while 36 reduced holdings. 16 funds opened positions while 31 raised stakes. 20.28 million shares or 1.20% more from 20.04 million shares in 2017Q3 were reported.
State Street has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Texas Permanent School Fund holds 0.01% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 23,931 shares. 1.63M were accumulated by Dimensional Fund Advsr L P. Pnc Svcs Grp Inc holds 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 1,422 shares. Blackrock stated it has 5.51M shares. Sei Invests invested in 67,175 shares or 0% of the stock. Winslow Evans And Crocker holds 0.01% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 1,758 shares. Parallax Volatility Advisers Limited Partnership invested in 5,544 shares. Citigroup invested in 135,472 shares or 0% of the stock. Stone Ridge Asset Mgmt Ltd Co holds 11,145 shares. Public Sector Pension Inv Board has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Matarin Cap Management Limited Liability reported 52,417 shares or 0.08% of all its holdings. 46,016 are held by Kbc Group Nv. Point72 Asset Lp has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Moreover, Arizona State Retirement Sys has 0.01% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report $0.09 EPS on May, 14.They anticipate $0.06 EPS change or 200.00 % from last quarter’s $0.03 EPS. AMPH’s profit would be $4.17 million giving it 53.64 P/E if the $0.09 EPS is correct. After having $0.10 EPS previously, Amphastar Pharmaceuticals, Inc.’s analysts see -10.00 % EPS growth. The stock decreased 0.87% or $0.17 during the last trading session, reaching $19.31. About 69,643 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 29.43% since April 23, 2017 and is uptrending. It has outperformed by 17.88% the S&P500.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Among 5 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Amphastar Pharmaceuticals had 9 analyst reports since October 26, 2017 according to SRatingsIntel. On Friday, October 27 the stock rating was maintained by Jefferies with “Buy”. Needham maintained it with “Buy” rating and $24.0 target in Tuesday, March 13 report. The stock has “Buy” rating by Piper Jaffray on Tuesday, January 30. The firm has “Market Perform” rating given on Friday, November 10 by BMO Capital Markets. The firm earned “Hold” rating on Thursday, October 26 by BMO Capital Markets. The rating was maintained by BMO Capital Markets on Tuesday, March 13 with “Market Perform”. The stock has “Hold” rating by Raymond James on Thursday, November 9. The rating was maintained by Needham with “Buy” on Friday, December 1. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Buy” rating given on Thursday, November 9 by Jefferies.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $895.03 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It has a 214.56 P/E ratio. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.